ABSTRACT
OBJECTIVE AND RESULTS DESCRIPTION: The study objective was to investigate the potential of quantitative measures of pulmonary inflammation by [18 F]Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) as a surrogate marker of inflammation in COPD. Patients treated with anti-inflammatory Liraglutide were compared to placebo and correlated with inflammatory markers. 27 COPD-patients (14 receiving Liraglutide treatment and 13 receiving placebo) underwent 4D-respiratory-gated FDG-PET/CT before and after treatment. Two raters independently segmented the lungs from CT images and measured activity in whole lung, mean standard uptake values (SUVmean) corrected for lean-body-mass in the phase-matched PET images of the whole segmented lung volume, and total lesion glycolysis (TLG; SUVmean multiplied by volume). Inter-rater reliability was analyzed with Bland-Altman analysis and correlation plots. We found no differences in metabolic activity in the lungs between the two groups as a surrogate of pulmonary inflammation, and no changes in inflammation markers. The purpose of the research and brief summary of main findings. The degree of and changes in pulmonary inflammation in chronic obstructive pulmonary disease (COPD) may be difficult to ascertain. Measuring metabolic activity as a surrogate marker of inflammation by FDG-PET/CT may be useful, but data on its use in COPD including reproducibility is still limited, especially with respiration-gated technique, which should improve quantification in the lungs. We assessed several quantitative measures of metabolic activity and correlated them with inflammation markers, and we assessed reproducibility of the methods. We found no differences in metabolic activity between the two groups (before and after 40 weeks treatment with Liraglutide vs. placebo). Bland-Altman analysis showed good agreement between the two raters. TRIAL REGISTRATION: The study was conducted between February 2018 and March 2020 at the Department of Pulmonary Diseases at Hospital South West Jutland and Lillebaelt Hospital, Denmark, and registered from March 2018 at clinicaltrials.gov with trial registration number NCT03466021.
Subject(s)
Fluorodeoxyglucose F18 , Lung , Positron Emission Tomography Computed Tomography , Pulmonary Disease, Chronic Obstructive , Humans , Pulmonary Disease, Chronic Obstructive/diagnostic imaging , Pulmonary Disease, Chronic Obstructive/drug therapy , Pulmonary Disease, Chronic Obstructive/metabolism , Positron Emission Tomography Computed Tomography/methods , Male , Female , Aged , Middle Aged , Lung/diagnostic imaging , Lung/drug effects , Lung/pathology , Lung/metabolism , Pneumonia/diagnostic imaging , Pneumonia/metabolism , Pneumonia/drug therapy , Liraglutide/therapeutic use , Liraglutide/pharmacology , Respiration/drug effects , RadiopharmaceuticalsSubject(s)
Diabetes Mellitus, Type 1/drug therapy , Diabetic Ketoacidosis/epidemiology , Hypoglycemic Agents/administration & dosage , Insulin Infusion Systems/adverse effects , Insulin/administration & dosage , Adult , Diabetic Ketoacidosis/etiology , Female , Humans , Incidence , Infusions, Subcutaneous/adverse effects , Male , Middle Aged , Young AdultABSTRACT
Chikungunya fever is an acute febrile illness associated with severe, often debilitating polyarthralgias. The disease is caused by the Chikungunya virus (CHIKV), an arthropod-borne virus that is transmitted to humans primarily via the bite of an infected mosquito. Since a re-emergence of CHIKV in 2004 in the Indian Ocean islands, the virus has spread into novel locations such as Europe. In Italy, an outbreak occurred in 2007. A mutation in CHIKV (E1-A226V) appears to improve virus survival in Ae. albopictus and also increase its virulence. Further attention should be given the disease since it is emerging in Europe.
